Showing results (371-380 of 933) with videos related to
Sort By:
Pageof 94
Blood|June 21, 2003
Rituximab in relapsed or refractory hairy cell leukemiaDeborah A Thomas, Susan O'Brien, Carlos Bueso-Ramos, et al.Cancer|April 28, 2011
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinibAlfonso Quintás-Cardama, Hagop Kantarjian, Jianqin Shan, et al.Cancer|October 26, 2007
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapiesGautam Borthakur, E Lin, Stefan Faderl, et al.Leukemia & Lymphoma|October 30, 2009
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapyEllen J Schlette, Joan Admirand, William Wierda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Elias Jabbour, Hagop M Kantarjian, Susan O'Brien, et al.Cancer|June 12, 2009
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phaseYesid Alvarado, Hagop Kantarjian, Susan O'Brien, et al.Cancer|June 22, 2010
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndromeAmit Lahoti, Hagop Kantarjian, Abdulla K Salahudeen, et al.Leukemia Research|April 6, 2010
Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemiaJean-Marie Bruey, Hagop Kantarjian, Wanlong Ma, et al.Cancer|January 7, 2010
Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemiaJeffrey J Tarrand, Michael J Keating, Apostolia M Tsimberidou, et al.Cancer|December 13, 2005
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyGautam Borthakur, Hagop Kantarjian, George Daley, et al.Pageof 94